Literature DB >> 26662569

The over-expression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5-fluorouracil towards gastric cancer.

Jingjing Li1,2, Yanwei Ye3,4, Min Wang5, Lisha Lu6, Chao Han7, Yubing Zhou7, Jingmin Zhang8, Zujiang Yu9, Xiefu Zhang2,10, Chunlin Zhao2,10, Jianguo Wen2, Quancheng Kan1.   

Abstract

The aim was to investigate the function of fibroblast growth factor receptor 4 (FGFR4) in gastric cancer (GC) and explore the treatment value of agent targeted to FGFR4. Function assays in vitro and in vivo were performed to investigate the discrepancy of biological features among the GC cells with different expression of FGFR4. GC cells were treated with the single and combination of PD173074 (PD, an inhibitor of FGFR4) and 5-fluorouracil (5-Fu). The invasion ability were stronger, and the apoptosis rates were lower in MGC803 and BGC823 cells treated with FGFR4-LV5 (over-expression of FGFR4 protein) (P < 0.05). The proliferation ability of GC cells is reduced when treated by the single and combination of 5-Fu and PD while that of the FGFR4-LV5 group was less inhibited compared with control group (P < 0.05). The apoptosis rates are remarkably increased in GC cells treated with the single and combination of 5-Fu and PD (P < 0.05). However, the apoptosis rate obviously is reduced in GC cells treated with FGFR4-LV5 compared with control group (P < 0.05). The expression of PCNA and Bcl-XL is remarkably decreased, and the expression of Caspase-3 and cleaved Caspase-3 is obviously increased in GC cells treated with the single and combination of 5-Fu and PD. The tumor volumes of nude mice in FGFR4-LV5 group were much more increased (P < 0.05). The over-expression of FGFR4 enhanced the proliferation ability of GC in vitro and in vivo. The combination of 5-Fu and PD exerted synergetic effect in weakening the proliferation ability and promoting apoptosis in GC cells, while the over-expression of FGFR4 might inhibit the efficacy of two drugs.

Entities:  

Keywords:  5-Fluorouracil; FGFR4; Gastric cancer; In vivo; PD173074

Mesh:

Substances:

Year:  2015        PMID: 26662569     DOI: 10.1007/s13277-015-4411-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  23 in total

1.  Combination of the FGFR4 inhibitor PD173074 and 5-fluorouracil reduces proliferation and promotes apoptosis in gastric cancer.

Authors:  Yan-Wei Ye; Shuang Hu; Ying-Qiang Shi; Xie-Fu Zhang; Ye Zhou; Chun-Lin Zhao; Guo-Jun Wang; Jian-Guo Wen; Hong Zong
Journal:  Oncol Rep       Date:  2013-10-11       Impact factor: 3.906

Review 2.  Cellular signaling by fibroblast growth factor receptors.

Authors:  V P Eswarakumar; I Lax; J Schlessinger
Journal:  Cytokine Growth Factor Rev       Date:  2005-02-01       Impact factor: 7.638

3.  The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression.

Authors:  Yanwei Ye; Yingqiang Shi; Ye Zhou; Chunyan Du; Chunmeng Wang; Heqin Zhan; Biqiang Zheng; Xi Cao; Meng-Hong Sun; Hong Fu
Journal:  Ann Surg Oncol       Date:  2010-09-16       Impact factor: 5.344

4.  Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.

Authors:  Shereen Ezzat; Ping Huang; Alan Dackiw; Sylvia L Asa
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

5.  The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo.

Authors:  Olivier E Pardo; John Latigo; Rosemary E Jeffery; Emma Nye; Richard Poulsom; Bradley Spencer-Dene; Nick R Lemoine; Gordon W Stamp; Eric O Aboagye; Michael J Seckl
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

6.  The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression.

Authors:  Jianghua Wang; David W Stockton; Michael Ittmann
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

Review 7.  HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.

Authors:  C Gravalos; A Jimeno
Journal:  Ann Oncol       Date:  2008-04-25       Impact factor: 32.976

8.  The correlations between the expression of FGFR4 protein and clinicopathological parameters as well as prognosis of gastric cancer patients.

Authors:  Yan-Wei Ye; Xiefu Zhang; Ye Zhou; Jianghong Wu; Chunlin Zhao; Lin Yuan; Guojun Wang; Chunyan Du; Chunmeng Wang; Yingqiang Shi
Journal:  J Surg Oncol       Date:  2012-05-14       Impact factor: 3.454

9.  Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.

Authors:  Han Kiat Ho; Sharon Pok; Sylvia Streit; Jens E Ruhe; Stefan Hart; Kah Suan Lim; Hooi Linn Loo; Myat Oo Aung; Seng Gee Lim; Axel Ullrich
Journal:  J Hepatol       Date:  2008-10-12       Impact factor: 25.083

10.  The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling.

Authors:  Kristine A Drafahl; Christopher W McAndrew; April N Meyer; Martin Haas; Daniel J Donoghue
Journal:  PLoS One       Date:  2010-12-22       Impact factor: 3.240

View more
  6 in total

Review 1.  FGFR4: A promising therapeutic target for breast cancer and other solid tumors.

Authors:  Kevin M Levine; Kai Ding; Lyuqin Chen; Steffi Oesterreich
Journal:  Pharmacol Ther       Date:  2020-05-31       Impact factor: 12.310

2.  Maelstrom promotes tumor metastasis through regulation of FGFR4 and epithelial-mesenchymal transition in epithelial ovarian cancer.

Authors:  Wei-Peng He; Gui-Ping Yang; Zun-Xian Yang; Hong-Wei Shen; Ze-Shan You; Guo-Fen Yang
Journal:  J Ovarian Res       Date:  2022-05-06       Impact factor: 4.234

3.  FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition.

Authors:  Yanwei Ye; Jie Li; Dongbao Jiang; Jingjing Li; Chuangfeng Xiao; Yingze Li; Chao Han; Chunlin Zhao
Journal:  Cancer Res Treat       Date:  2020-05-25       Impact factor: 4.679

4.  Comprehensive analysis of the prognostic value and immune infiltration of FGFR family members in gastric cancer.

Authors:  Chengcheng Yang; Dingli Song; Fengyu Zhao; Jie Wu; Boxiang Zhang; Hong Ren; Qi Sun; Sida Qin
Journal:  Front Oncol       Date:  2022-09-06       Impact factor: 5.738

5.  Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.

Authors:  Kai Hung Tiong; Boon Shing Tan; Heng Lungh Choo; Felicia Fei-Lei Chung; Ling-Wei Hii; Si Hoey Tan; Nelson Tze Woei Khor; Shew Fung Wong; Sze-Jia See; Yuen-Fen Tan; Rozita Rosli; Soon-Keng Cheong; Chee-Onn Leong
Journal:  Oncotarget       Date:  2016-09-06

Review 6.  FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?

Authors:  Csongor G Lengyel; Sadaqat Hussain; Andreas Seeber; Sara Jamil Nidhamalddin; Dario Trapani; Baker S Habeeb; Essam Elfaham; Syed Ayub Mazher; Fahmi Seid; Shah Z Khan; Khalid El Bairi; Andrew Odhiambo; Sara C Altuna; Angelica Petrillo
Journal:  Life (Basel)       Date:  2022-01-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.